Abstract
Pregnancy is becoming a relatively common event in patients with pituitary tumors (PT), due to the increasing availability of medical treatments, which control pituitary diseases associated with the development of PT. However, the presence of PT and its treatment may be a disturbing factor for pregnancy, and pregnancy significantly influences the course and the management of PT. This review summarizes the knowledge about the management of PT during pregnancy and the occurrence of pregnancy in patients with pre-existent PT, focusing on secreting PT characterized by hormonal excess and on clinically non-functioning PT often associated to hormone deficiency, which configure the hypopituitaric syndrome.




Similar content being viewed by others
References
Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV (1990) The pituitary gland in pregnancy. A clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65:461–474
Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (eds) (2011) Williams textbook of endocrinology, 12th edn. Saunders Elsevier, Philadelphia
Molitch ME (2003) Pituitary tumors and pregnancy. GH IGF Res 13:S38–S44
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101(3):613–619
Beckers A, Daly AF (2007) The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 157(4):371–382
Moertini P, Losa M, Barzaghi R, Boari N, Giovanelli M (2005) Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 56(6):1222–1233
Hirshfeld-Cytron J, Kim HH (2006) Treatment of fertility in women with pituitary tumors. Expert Rev Anticancer Ther 6(9 Suppl):s55–s62
Chandrashekar V, Zaczek D, Bartke A (2004) The consequences of altered somatotropic system on reproduction. Biol Reprod 71(1):17–27
Levy J (1995) Endogenous plasma GH and the occurrence of pregnancies in patients undergoing in vitro fertilization and embryo transfer with ovarian stimulation. Human Reprod 10:1065–1069
Chrousos GP, Torpy DJ, Gold PW (1998) Interactions between the hypothalamic–pituitary–adrenal axis and the female reproductive system: clinical implications. Ann Int Med 129(3):229–240
Cooke PS, Holsberger DR, Witorsch RJ, Sylvester PW, Meredith JM, Treinen KA, Chapin RE (2004) Thyroid hormone, glucocorticoids, and prolactin at the nexus of physiology, reproduction, and toxicology. Toxicol Appl Pharmacol 194:309–335
Poppe K, Velkeniers B, Glinoer D (2007) Thyroid disease and female reproduction. Clin Endocrinol (Oxf) 66(3):309–321
Dinc H, Esen F, Demirci A, Sari A, Resit Gumele H (1998) Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 39:64–69
Elster AD, Sanders TG, Vines FS, Chen MY (1991) Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. Radiology 181:531–535
Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85:217–220
Waters MJ, Kaye PL (2002) The role of growth hormone in fetal development. Growth Hormon IGF Res 12:137–146
Frankenne F, Closset J, Gomez F, Scippo ML, Smal J, Hennen G (1988) The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 66:1171–1180
Eriksson L, Frankenne F, Eden S, Hennen G, Von Schoultz B (1989) Growth hormone 24-h serum profiles during pregnancy lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 106:949–953
Beckers A, Stevenaert A, Foidart J-M, Hennen G, Frankenne F (1990) Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 71:725–731
Winter JSD (1998) Fetal and neonatal adrenocortical physiology. In: Polin RA, Fox WW (eds) Maternal–fetal endocrinology. WB Saunders, Philadelphia, pp 2447–2459
Liggins GC (1994) The role of cortisol in preparing the fetus for birth. Reprod Fertil Dev 6:141–150
Pepe GJ, Albrecht ED (1990) Regulation of the primate fetal adrenal cortex. Endocr Rev 11:151–176
Mastorakos G, Ilias I (2003) Maternal and fetal hypothalamic–pituitary–adrenal axes during pregnancy and postpartum. Ann N Y Acad Sci 997:136–149
Lindsay JR, Nieman LK (2005) The hypothalamic–pituitary–adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 26(6):775–799
Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK (2005) Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90(5):3077–3083
Nolten WE, Lindheimer MD, Rueckert PA, Oparil S, Ehrlich EN (1980) Diurnal patterns and regulation of cortisol secretion in pregnancy. J Clin Endocrinol Metab 51:466–472
Fisher DA, Nelson JC, Carlton EI, Wilcox RB (2000) Maturation of human hypothalamic–pituitary–thyroid function and control. Thyroid 10:229–234
Vulsma T, Gons MH, de Vijlder JJ (1989) Maternal–fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 321:13–16
Glinoer D, de Nayer P, Bourdoux P, Lemone M, Robyn C, van Steirteghem A, Kinthaert J, Lejeune B (1990) Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 71(2):276–287
Soldin OP (2006) Thyroid function testing in pregnancy and thyroid disease: trimester-specific reference intervals. Ther Drug Monit 28(1):8–11
Kredentser JV, Hoskins CF, Scott JZ (1981) Hyperprolactinemia: a significant factor in female infertility. Am J Obstet Gynecol 139:264–267
Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534
Molitch ME (1999) Diagnosis and treatment of prolactinomas. Adv Intern Med 44:117–153
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF, The Cabergoline Comparative Study Group (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265–273
Herman-Bonert V, Seliverstow M, Melmed S (1998) Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 83:727–731
Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155(2):279–284
Grasso LFS, Pivonello R, Auriemma RS, Galdiero M, De Leo M, Cozzolino A, Vitale P, Simeoli C, Lombardi G, Colao A (2010) Acromegaly and women fertility. Minerva Endocrinol 35(4):13–26
Beuscher MA, McClamrock HD, Adashi EY (1992) Cushing’s syndrome in pregnancy. Obstet Gynecol 79:130–137
Benoit R, Pearson-Murphy BE, Robert F, Marcovitz S, Hardy J, Tsoukas G, Gardiner RJ (1980) Hyperthyroidism due to a pituitary TSH secreting tumour with amenorrhoea-galactorrhoea. Clin Endocrinol 12(1):11–19
Kupersmith MJ, Rosenberg C, Kleinberg D (1994) Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 121:473–477
Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352:1455–1461
Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574–3579
Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247–2252
Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256–5261
Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol 53:53–60
Colao A, Lombardi G, Annunziato L (2000) Cabergoline. Expert Opin Pharmacother 1:555–574
Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312:1364–1370
Musolino NR, Bronstein MD (2001) Prolactinomas and pregnancy. In: Bronstein MD (ed) Pituitary tumors and pregnancy. Kluwer Academic Publishers, Norwell, pp 91–108
Auriemma RS, Perone Y, Di Sarno A, Grasso LFS, Guerra E, Gasperi M, Pivonello R, Colao A (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98:372–379
Krupp P, Monka C, Richter K (1988) The safety aspects of infertility treatments. In: Proceedings of the second world congress of gynecology and obstetrics, Rio de Janeiro, p 9
Konopka P, Raymond JP, Merceron RE, Seneze J (1983) Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 146(8):935–938
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522
Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68(1):66–71 Epub 2007 Aug 29
Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M, Lavezzari M, Nicolosi AE, Ferrero S, Landi ML, Beck-Peccoz P, Bonati M (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16:791–793
Robert E, Musatti L, Piscitelli G, Ferrari CI (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10:333–337
Molitch ME (2011) Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 25(6):885–889
Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95(6):2672–2679
Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) 73(2):236–242
Stalldecker G, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L, Chervin A, Danilowicz K, Diez S, Fainstein-Day P, García-Basavilbaso N, Glerean M, Gollan V, Katz D, Loto MG, Manavela M, Rogozinski AS, Servidio M, Vitale NM (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345–350
De Mari M, Zenzola A, Lamberti P (2002) Antiparkinsonian treatment in pregnancy. Mov Disord 17:428–429
Acharya V (2004) Review of pregnancy reports in patients on pergolide treatment. Eli Lilly Co., Indianapolis
Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14(4):228–238
Brodsky JB, Cohen EN, Brown BW Jr, Wu ML, Whitcher C (1980) Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 138:1165–1167
Rossi AM, Vilska S, Heinonen PK (1995) Outcome of pregnancies in women with treated or untreated hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 63:143–146
Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P (1989) Is pregnancy the best treatment for hyperprolactinemia? Hum Reprod 4(8):910–912
Ikegami H, Aono T, Koizumi K, Koike K, Fukui H, Tanizawa O (1987) Relationship between the methods of treatment for prolactinomas and the puerperal lactation. Fertil Steril 47(5):867–869
Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 35:99–116
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152
Melmed S (1990) Acromegaly. N Engl J Med 322:966–977
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 358:1754–1759
Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467–477
Atmaca A, Dagdelen S, Erbas T (2006) Follow-up of pregnancy in acromegalic women: different presentations and outcomes. Exp Clin Endocrinol Diabetes 114(3):135–139
Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518–523
Blackhurst G, Strachan MW, Collie D, Gregor A, Statham PF, Seckl JE (2002) The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol (Oxf) 57:401–404
Boulanger C, Vezzosi D, Bennet A, Lorenzini F, Fauvel J, Caron P (2004) Normal pregnancy in a woman with nesidioblastosis treated with somatostatin analog octreotide. J Endocrinol Invest 27(5):465–470
Caron P, Gerbeau C, Pradayrol L, Simonetta C, Bayard F (1996) Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Clin Endocrinol Metab 81:1164–1168
Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE (2007) Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92(9):3374–3377
Cheng V, Faiman C, Kennedy L, Khoury F, Hatipoglu B, Weil R, Hamrahian A (2012) Pregnancy and acromegaly: a review. Pituitary 15:59–63
Maffei P, Tamagno G, Nardelli GB, Milan G, Martini C, DeCarlo E, Dassie F, Vettor R, Sicolo N (2010) Treatment with somatostatin analogs in acromegalic women during pregnancy. Minerva Endocrinol 35(4):49–69
Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95:4680–4687
Cheng S, Grasso LFS, Martinez-Orozco JA, Al-Agha R, Pivoenllo R, Colao A, Ezzat S (2012) Pregnancy in acromegaly: experience from two referral centers and systematic review of literature. Clin Endocrinol 76:264–271
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JAH, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16:294–302
Bevan JS, Gough MH, Gillmer MD, Burke CW (1987) Cushing’s syndrome in pregnancy: the timing of definitive treatment. Clin Endocrinol 27(2):225–233
Aron DC, Schnall AM, Sheeler LR (1990) Cushing’s syndrome and pregnancy. Am J Obstet Gynecol 162:244–252
Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A (2008) Cushing’s syndrome. Endocrinol Metab Clin North Am 37(1):135–149
Chico A, Manzanares JM, Halperin I, Martonez de Osaba MJ, Adelantado J, Webb SM (1996) Cushing’s disease and pregnancy. Eur J Obstet Gynecol Reprod Biol 64:143–146
Guilhaume B, Sanson ML, Billaud L, Bertagna X, Laudat MH, Luton JP (1992) Cushing’s syndrome and pregnancy: aetiologies and prognosis in twenty-two patients. Eur J Med 1(2):83–89
Lekarev O, New MI (2011) Adrenal disease in pregnancy. Best Pract Res Clin Endocrinol Metab 25(6):959–973
Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17(6):610–638
Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD (1999) Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 84(2):476–486
Chaiamnuay S, Moster M, Katz MR, Kim YN (2003) Successful management of a pregnant woman with a TSH secreting pituitary adenoma with surgical and medical therapy. Pituitary 6(2):109–113
Murata Y, Ando H, Nagasaka T, Takahashi I, Saito K, Fukugaki H, Matsuzawa K, Mizutani S (2003) Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 88(5):1988–1993
Sedgh G et al (2012) Induced abortion: incidence and trends worldwide from 1995 to 2008. Lancet. doi:10.1016/S0140-6736(11)61786-8
Conflict of interest
AC has been principal investigator of research studies from Novartis, Ipsen, Pfizer and Lilly, has received research grants from Ferring, Lilly, Ipsen, Merck-Serono, Novartis, Novo-Nordisk and Pfizer, has been occasional consultant for Novartis, Ipsen and Pfizer, and has received fees and honoraria from Ipsen, Novartis, and Pfizer. RP has been principal investigator of research studies from Novartis, has received research grants from Novartis, Pfizer, Viropharma and IBSA, has been occasional consultant for Novartis, Ipsen, Pfizer, Viropharma, Ferring, Italfarmaco and received fees and honoraria for presentations from Novartis. MCDM, RSA, CA, LFSG, AC, MDL, GDP, GL have nothing to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pivonello, R., De Martino, M.C., Auriemma, R.S. et al. Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. J Endocrinol Invest 37, 99–112 (2014). https://doi.org/10.1007/s40618-013-0019-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-013-0019-8